HUE045810T2 - MET és VEGF kettõs inhibitorai kasztrációrezisztens prosztatarák és oszteoblasztos csontáttétek kezelésére - Google Patents

MET és VEGF kettõs inhibitorai kasztrációrezisztens prosztatarák és oszteoblasztos csontáttétek kezelésére

Info

Publication number
HUE045810T2
HUE045810T2 HUE11764655A HUE11764655A HUE045810T2 HU E045810 T2 HUE045810 T2 HU E045810T2 HU E11764655 A HUE11764655 A HU E11764655A HU E11764655 A HUE11764655 A HU E11764655A HU E045810 T2 HUE045810 T2 HU E045810T2
Authority
HU
Hungary
Prior art keywords
castration
vegf
met
treatment
prostate cancer
Prior art date
Application number
HUE11764655A
Other languages
English (en)
Inventor
David Smith
Maha Hussain
Original Assignee
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44741730&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUE045810(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Exelixis Inc filed Critical Exelixis Inc
Publication of HUE045810T2 publication Critical patent/HUE045810T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
HUE11764655A 2010-09-27 2011-09-26 MET és VEGF kettõs inhibitorai kasztrációrezisztens prosztatarák és oszteoblasztos csontáttétek kezelésére HUE045810T2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38695910P 2010-09-27 2010-09-27
US201161481671P 2011-05-02 2011-05-02

Publications (1)

Publication Number Publication Date
HUE045810T2 true HUE045810T2 (hu) 2020-01-28

Family

ID=44741730

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE11764655A HUE045810T2 (hu) 2010-09-27 2011-09-26 MET és VEGF kettõs inhibitorai kasztrációrezisztens prosztatarák és oszteoblasztos csontáttétek kezelésére

Country Status (22)

Country Link
US (4) US20140057943A1 (hu)
EP (1) EP2621481B2 (hu)
JP (2) JP6158705B2 (hu)
KR (1) KR101882328B1 (hu)
CN (1) CN103402505A (hu)
AR (1) AR085195A1 (hu)
AU (2) AU2011307304C1 (hu)
BR (1) BR112013007220A2 (hu)
CA (1) CA2812750C (hu)
DK (1) DK2621481T4 (hu)
EA (1) EA027476B1 (hu)
ES (1) ES2754973T5 (hu)
FI (1) FI2621481T4 (hu)
HU (1) HUE045810T2 (hu)
IL (1) IL225507B (hu)
MX (1) MX352926B (hu)
PL (1) PL2621481T5 (hu)
PT (1) PT2621481T (hu)
SI (1) SI2621481T2 (hu)
TW (2) TW201738213A (hu)
UA (1) UA114172C2 (hu)
WO (1) WO2012044572A1 (hu)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106420743A (zh) 2010-07-16 2017-02-22 埃克塞里艾克西斯公司 C‑met调节剂药物组合物
WO2012044572A1 (en) 2010-09-27 2012-04-05 Exelixis, Inc. Dual inhibitors of met and vegf for the treatment of castration- resistant prostate cancer and osteoblastic bone metastases
BR112013020362A2 (pt) 2011-02-10 2018-05-29 Exelixis Inc processos para a preparação de compostos de quinolina, compostos e combinações farmacêuticas que os contem
US20120252840A1 (en) 2011-04-04 2012-10-04 Exelixis, Inc. Method of Treating Cancer
KR20140025496A (ko) * 2011-05-02 2014-03-04 엑셀리시스, 인코포레이티드 암 및 뼈 암 통증의 치료방법
BR112014006702A2 (pt) * 2011-09-22 2017-06-13 Exelixis Inc método para tratar osteoporose
CA2852771C (en) 2011-10-20 2019-11-26 Exelixis, Inc. Process for preparing quinoline derivatives
TW201818937A (zh) * 2011-11-08 2018-06-01 美商艾克塞里克斯公司 治療癌症之方法
JP2015515988A (ja) 2012-05-02 2015-06-04 エクセリクシス， インク． 溶骨性骨転移を治療するためのｍｅｔ−ｖｅｇｆ二重調節剤
CN103664776B (zh) * 2012-09-26 2016-05-04 正大天晴药业集团股份有限公司 一种酪氨酸激酶抑制剂及其中间体的制备方法
MX366003B (es) 2013-03-15 2019-06-24 Exelixis Inc Metabolitos de n-(4-{[6,7-bis(metiloxi)quinolin-4-il]oxi}fenil)-n' -(4-fluorofenil)ciclopropan-1,1-dicarboxamida.
KR20150138268A (ko) * 2013-04-04 2015-12-09 엑셀리시스, 인코포레이티드 암을 치료하기 위한 약물 병용요법
US11564915B2 (en) 2013-04-04 2023-01-31 Exelixis, Inc. Cabozantinib dosage form and use in the treatment of cancer
MX2021001583A (es) 2014-02-14 2023-02-08 Exelixis Inc Formas sólidas cristalinas de n-{4-[(6,7-dimetoxiquinolin-4-il)oxi ] fenil}-n'-(4-fluorofenil)ciclopropan-1,1-dicarboxamida, procesos para elaboración y métodos de uso.
US10159666B2 (en) 2014-03-17 2018-12-25 Exelixis, Inc. Dosing of cabozantinib formulations
CN104788372B (zh) * 2014-07-25 2018-01-30 上海圣考医药科技有限公司 一种氘代卡博替尼衍生物、其制备方法、应用及其中间体
CN106715397B (zh) 2014-07-31 2021-07-23 埃克塞里艾克西斯公司 制备氟-18标记的卡博替尼及其类似物的方法
EP3177311A1 (en) 2014-08-05 2017-06-14 Exelixis, Inc. Drug combinations to treat multiple myeloma
EP3219205A1 (en) * 2016-03-18 2017-09-20 Nihon Medi-Physics Co., Ltd. Method for producing a non human animal model of osteoblastic bone metastasis
EP3442531A1 (en) 2016-04-15 2019-02-20 Exelixis, Inc. Method of treating renal cell carcinoma using n-(4-(6,7-dimethoxyquinolin-4-yloxy) phenyl)-n'-(4-fluoropheny)cyclopropane-1,1-dicarboxamide, (2s)-hydroxybutanedioate
CN108503650B (zh) * 2017-02-27 2021-02-12 北京赛特明强医药科技有限公司 二噁烷并喹唑啉类化合物或其药用盐或其水合物及其作为酪氨酸激酶抑制剂的应用
WO2019154133A1 (zh) * 2018-02-11 2019-08-15 北京赛特明强医药科技有限公司 二噁烷并喹啉类化合物及其制备方法与应用
MA48776A (fr) 2017-05-26 2020-04-08 Exelixis Inc Formes solides cristallines de sels de n-{4-[(6,7-diméthoxyquinolin-4-yl) oxy]phényl}-n'-(4-fluorphényl) cyclopropane-1,1-dicarboxamide, procédés de préparation et d'utilisation
AU2018395222B2 (en) 2017-12-27 2023-06-08 Coa Therapeutics, Inc. Small molecule modulators of pantothenate kinases
AU2018397486A1 (en) 2017-12-27 2020-08-13 Coa Therapeutics, Inc. Methods of treating disorders associated with castor
CR20230287A (es) 2018-01-26 2023-07-26 Exelixis Inc COMPUESTOS PARA EL TRATAMIENTO DE TRASTORNOS DEPENDIENTES DE CINASAS (Divisional 2020-358)
EP4262814A1 (en) * 2020-12-16 2023-10-25 St. Jude Children's Research Hospital, Inc. Methods of treating disorders associated with castor

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4107288A (en) 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
WO2003033472A1 (fr) 2001-10-17 2003-04-24 Kirin Beer Kabushiki Kaisha Derives de quinoline ou de quinazoline inhibant l'autophosphorylation de recepteurs du facteur de croissance des fibroblastes
GB0219746D0 (en) 2002-08-23 2002-10-02 Inst Of Ex Botany Ascr Azapurine derivatives
WO2004035572A1 (ja) 2002-10-21 2004-04-29 Kirin Beer Kabushiki Kaisha Ｎ−｛２−クロロ−４−［（６，７−ジメトキシ−４−キノリル）オキシ］フェニル｝−ｎ’−（５−メチル−３−イソキサゾリル）ウレアの塩の結晶形
AU2003280599A1 (en) 2002-10-29 2004-05-25 Kirin Beer Kabushiki Kaisha QUINOLINE DERIVATIVES AND QUINAZOLINE DERIVATIVES INHIBITING AUTOPHOSPHORYLATION OF Flt3 AND MEDICINAL COMPOSITIONS CONTAINING THE SAME
KR101089462B1 (ko) 2002-11-04 2011-12-07 아스트라제네카 아베 Ｓｒｃ 티로신 키나제 억제제로서의 퀴나졸린 유도체
MXPA05006123A (es) 2002-12-13 2005-09-30 Neurogen Corp Analogos de quinazolin-4-ilamina 2-sustituida como moduladores de receptores de capsaicina.
MXPA05006335A (es) 2002-12-18 2005-08-26 Pfizer Prod Inc Derivados biciclicos para el tratamiento del crecimiento celular anormal.
EP1575591A4 (en) 2002-12-23 2007-09-12 Ariad Pharma Inc HETEROCYCLES AND ITS USE
AU2003292838A1 (en) 2002-12-27 2004-07-29 Kirin Beer Kabushiki Kaisha Therapeutic agent for wet age-related macular degeneration
DK2392564T3 (da) † 2003-09-26 2014-01-13 Exelixis Inc c-Met-modulatorer og anvendelsesfremgangsmåder
WO2006014325A2 (en) 2004-07-02 2006-02-09 Exelixis, Inc. C-met modulators and method of use
WO2006108059A1 (en) 2005-04-06 2006-10-12 Exelixis, Inc. C-met modulators and methods of use
US20080004273A1 (en) 2006-05-30 2008-01-03 Stephane Raeppel Inhibitors of protein tyrosine kinase activity
WO2008076415A1 (en) 2006-12-14 2008-06-26 Exelixis, Inc. Methods of using mek inhibitors
WO2008083319A1 (en) 2006-12-29 2008-07-10 Il Yang Pharmaceutical Company, Ltd. Solid state forms of enantiopure ilaprazole
PL2183254T3 (pl) * 2007-08-29 2017-10-31 Methylgene Inc Inhibitory aktywności białkowej kinazy tyrozynowej
TW200922590A (en) * 2007-09-10 2009-06-01 Curis Inc VEGFR inhibitors containing a zinc binding moiety
UY31800A (es) 2008-05-05 2009-11-10 Smithkline Beckman Corp Metodo de tratamiento de cancer usando un inhibidor de cmet y axl y un inhibidor de erbb
WO2009140549A1 (en) * 2008-05-14 2009-11-19 Amgen Inc. Combinations vegf(r) inhibitors and hepatocyte growth factor (c-met) inhibitors for the treatment of cancer
AR075084A1 (es) 2008-09-26 2011-03-09 Smithkline Beecham Corp Metodo de preparacion de quinolinil -oxidifenil - ciclopropanodicarboxamidas e intermediarios correspondientes
CA2738583A1 (en) 2008-10-01 2010-04-08 Ludwig Institute For Cancer Research Methods for the treatment of cancer
KR20110084455A (ko) 2008-11-13 2011-07-22 엑셀리시스, 인코포레이티드 퀴놀린 유도체를 제조하는 방법
JP2010126530A (ja) * 2008-12-01 2010-06-10 Takeda Chem Ind Ltd 縮合複素環誘導体およびその用途
WO2010065838A1 (en) 2008-12-04 2010-06-10 Exelixis, Inc. Methods of preparing quinoline derivatives
SG173014A1 (en) * 2009-01-16 2011-08-29 Exelixis Inc Malate salt of n- (4- { [ 6, 7-bis (methyloxy) quin0lin-4-yl] oxy}phenyl)-n' - (4 -fluorophenyl) cyclopropane-1,1-dicarboxamide, and crystalline forms therof for the treatment of cancer
CA2768370A1 (en) 2009-07-17 2011-01-20 Exelixis, Inc. Crystalline forms of n-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]-quinolin-4-yl}oxy)phenyl]-n'-(4-fluorophenyl)cyclopropane-1, 1-dicarboxamide
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
WO2011031840A1 (en) 2009-09-09 2011-03-17 Quintiles Transnational Corp. Methods and compositions for the treatment of receptor tyrosine kinase mediated diseases or disorders
MX2012010506A (es) 2010-03-12 2012-10-15 Exelixis Inc Formas cristalinas hidratadas del n-[3-fluoro-4-({6-(metiloxi)-7-[ (3-morfolin-4-ilpropil)oxi]-quinolin-4-il}oxi)fenil]-n'-(4-fluoro fenil)ciclopropano-1,1-dicarboxamida.
US20120070368A1 (en) 2010-04-16 2012-03-22 Exelixis, Inc. Methods of Using C-Met Modulators
CN106420743A (zh) 2010-07-16 2017-02-22 埃克塞里艾克西斯公司 C‑met调节剂药物组合物
EP2593091A1 (en) 2010-07-16 2013-05-22 Exelixis, Inc. C-met modulator pharmaceutical compositions
AU2011307306A1 (en) 2010-09-27 2013-05-02 Exelixis, Inc. Dual inhibitors of MET and VEGF for the treatment of castration resistant prostate cancer and osteoblastic bone metastases
EP2621483A1 (en) 2010-09-27 2013-08-07 Exelixis, Inc. Dual inhibitors of met and vegf for the treatment of castration resistant prostate cancer and osteoblastic bone metastases
WO2012044572A1 (en) 2010-09-27 2012-04-05 Exelixis, Inc. Dual inhibitors of met and vegf for the treatment of castration- resistant prostate cancer and osteoblastic bone metastases
EP2643001A4 (en) 2010-11-22 2014-02-19 Glaxosmithkline Ip Dev Ltd METHOD OF TREATING CANCER
BR112013020362A2 (pt) 2011-02-10 2018-05-29 Exelixis Inc processos para a preparação de compostos de quinolina, compostos e combinações farmacêuticas que os contem
US20120252840A1 (en) 2011-04-04 2012-10-04 Exelixis, Inc. Method of Treating Cancer
KR20140025496A (ko) 2011-05-02 2014-03-04 엑셀리시스, 인코포레이티드 암 및 뼈 암 통증의 치료방법
TW201306842A (zh) 2011-06-15 2013-02-16 Exelixis Inc 使用ｐｉ３ｋ／ｍｔｏｒ吡啶並嘧啶酮抑制劑及苯達莫司汀及／或利妥昔單抗治療惡性血液疾病之組合療法
BR112014006702A2 (pt) 2011-09-22 2017-06-13 Exelixis Inc método para tratar osteoporose
CA2852771C (en) 2011-10-20 2019-11-26 Exelixis, Inc. Process for preparing quinoline derivatives
TW201818937A (zh) 2011-11-08 2018-06-01 美商艾克塞里克斯公司 治療癌症之方法
JP2015515988A (ja) 2012-05-02 2015-06-04 エクセリクシス， インク． 溶骨性骨転移を治療するためのｍｅｔ−ｖｅｇｆ二重調節剤
CN114129566A (zh) 2012-09-07 2022-03-04 埃克塞里艾克西斯公司 用于治疗肺腺癌的met、vegfr和ret的抑制剂
US20140221372A1 (en) 2013-02-06 2014-08-07 GlaxoSmithKline Intellectual Property (NO 2.) Limited Method of administration and treatment
MX366003B (es) 2013-03-15 2019-06-24 Exelixis Inc Metabolitos de n-(4-{[6,7-bis(metiloxi)quinolin-4-il]oxi}fenil)-n' -(4-fluorofenil)ciclopropan-1,1-dicarboxamida.
KR20150138268A (ko) 2013-04-04 2015-12-09 엑셀리시스, 인코포레이티드 암을 치료하기 위한 약물 병용요법

Also Published As

Publication number Publication date
TW201738213A (zh) 2017-11-01
EA027476B1 (ru) 2017-07-31
PL2621481T5 (pl) 2023-03-13
US20140057943A1 (en) 2014-02-27
KR101882328B1 (ko) 2018-07-27
US20200330450A1 (en) 2020-10-22
AR085195A1 (es) 2013-09-18
JP2013537916A (ja) 2013-10-07
US11612597B2 (en) 2023-03-28
AU2011307304A1 (en) 2013-05-02
ES2754973T5 (es) 2023-03-13
EA201390465A1 (ru) 2013-08-30
IL225507A0 (en) 2013-06-27
US20230301980A1 (en) 2023-09-28
FI2621481T4 (fi) 2023-01-13
MX352926B (es) 2017-12-14
JP6158705B2 (ja) 2017-07-05
SI2621481T1 (sl) 2019-11-29
DK2621481T3 (da) 2019-10-21
EP2621481A1 (en) 2013-08-07
CA2812750A1 (en) 2012-04-05
WO2012044572A1 (en) 2012-04-05
US20160220554A1 (en) 2016-08-04
DK2621481T4 (da) 2023-01-09
KR20140025304A (ko) 2014-03-04
UA114172C2 (uk) 2017-05-10
CA2812750C (en) 2020-10-06
AU2011307304C1 (en) 2016-10-20
ES2754973T3 (es) 2020-04-21
IL225507B (en) 2019-08-29
CN103402505A (zh) 2013-11-20
SI2621481T2 (sl) 2023-02-28
PT2621481T (pt) 2019-11-19
AU2016204747A1 (en) 2016-07-28
TW201302709A (zh) 2013-01-16
US11969419B2 (en) 2024-04-30
EP2621481B2 (en) 2022-10-19
BR112013007220A2 (pt) 2017-08-08
PL2621481T3 (pl) 2020-03-31
AU2011307304B2 (en) 2016-04-14
MX2013003594A (es) 2013-08-01
EP2621481B1 (en) 2019-08-14
JP2017149714A (ja) 2017-08-31

Similar Documents

Publication Publication Date Title
IL225507B (en) Dual inhibitors of met and vegf for the treatment of castration-resistant prostate cancer and osteoblastic bone metastasis
IL276362A (en) Cancer treatment methods
HK1202062A1 (en) Dual inhibitor of met and vegf for treating cancer met vegf
SG10201508495VA (en) Combination treatment of cancer
HRP20170225T1 (hr) Fosfoplatini i njihova uporaba za liječenje karcinoma
HK1189272A1 (zh) 治療癌症的方法
EP2640390A4 (en) METHODS OF TREATING CANCER
EP2911692A4 (en) USE OF ENDOCYTOSE INHIBITORS AND ANTIBODIES FOR ANTICANCER THERAPY
EP2635273A4 (en) ISOFLAVONOID COMPOSITIONS AND METHOD FOR CANCER TREATMENT
PT2619331T (pt) Métodos de tratamento de cancro incluindo rastreio de nqo1
EP2547368A4 (en) METHOD AND COMPOSITIONS FOR CANCER TREATMENT
ZA201202379B (en) Antagonists of dsgs2 for treatment of cancer
WO2012037553A9 (en) Use of pkc-iota inhibitors for the treatment of breast cancer
GB201017354D0 (en) Treatment of cancer
GB201017356D0 (en) Combination treatment of cancer
IL221238A0 (en) Pharmaceutical compositions and methods for the treatment and prevention of cancer
HU1000559D0 (en) Pharmaceutical compositions for the treatment of osteoporosis and cancer